Albertini, Mark R. http://orcid.org/0000-0002-6499-517X
Ranheim, Erik A.
Zuleger, Cindy L.
Sondel, Paul M.
Hank, Jacquelyn A.
Bridges, Alan
Newton, Michael A.
McFarland, Thomas
Collins, Jennifer
Clements, Erin
Henry, Mary Beth
Neuman, Heather B.
Weber, Sharon
Whalen, Giles
Galili, Uri
Funding for this research was provided by:
National Institutes of Health (CA130295)
National Cancer Institute (P30 CA014520)
William S. Middleton Memorial Veterans Hospital (Institutional support)
Clinical and Translational Science Award (UL1TR000427)
Ann's Hope Foundation (Melanoma Research Award)
Tim Eagle Memorial (Melanoma Research Award)
Jay Van Sloan Memorial from the Steve Leuthold Family (Melanoma Research Award)
Gretchen and Andrew Dawes Melanoma Research Fund (Melanoma Research Award)
Agalimmune (Melanoma Research Award)
Article History
Received: 14 January 2016
Accepted: 8 May 2016
First Online: 20 May 2016
Compliance with ethical standards
:
: The authors have the following financial or other conflicts of interests to disclose related to this publication: Uri Galili is the inventor of this immunotherapy and is a consultant to Agalimmune Inc. which further develops cancer immunotherapy with α-gal glycolipids. All other authors declare no financial or other conflicts of interests related to this publication.
: The UW Human Subjects Committee and the FDA approved this study (IND 12946). Informed consent was obtained from all individual participants included in the study and all individual participants registered with the Biostatistics Registration Desk prior to treatment. The clinical trial registration number for this study is: NCT00668512. All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.